|
¸ÞµðÄɾîÆÊ |
±ä±Þ¸ðÁý/ÀÇ·á¼Ò¸ðÇ°+ÀǾ൵¸Å+°£È£½Ç½À¹°Ç° ³³Ç°¿µ¾÷ °æ·Â
°æ±â ºÎõ½Ã ¿ø¹Ì±¸, °æ±â ºÎõ½Ã ¿ÀÁ¤±¸, °æ±â ºÎõ½Ã ¼Ò»ç±¸ | Çз¹«°ü |
¹è¼Û/³³Ç°/¿îÀü±â»ç |
3³â¡è |
ä¿ë½Ã |
06.22 |
|
|
Àϻ꺹À½ÀçÈ°¿ä¾çº´¿ø |
Àϻ꺹À½ÀçÈ°¿ä¾çº´¿ø ¾à»ç ä¿ë°ø°í
°æ±â °í¾ç½Ã Àϻ걸 | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
°æ·Â¹«°ü |
ä¿ë½Ã |
04.18 |
|
|
Veeva Systems Korea YH |
Senior Consultant - R&D Vault
¼¿ï ¼Ãʱ¸ | Çз¹«°ü |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
°æ·Â¹«°ü |
»ó½Ãä¿ë |
04.24 |
|
|
Veeva Systems Korea YH |
CRM Consultant
¼¿ï ¼Ãʱ¸ | Çз¹«°ü |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
°æ·Â¹«°ü |
»ó½Ãä¿ë |
04.24 |
|
|
Veeva Systems Korea YH |
Account Executive - R&D Vault
¼¿ï ¼Ãʱ¸ | Çз¹«°ü |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
°æ·Â¹«°ü |
»ó½Ãä¿ë |
04.24 |
|
|
Veeva Systems Korea YH |
Solution Consultant - Vault R&D
¼¿ï ¼Ãʱ¸ | Çз¹«°ü |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
°æ·Â¹«°ü |
»ó½Ãä¿ë |
04.24 |
|
|
À̴ϽºÆ®¹ÙÀÌ¿ÀÁ¦¾à(ÁÖ) |
À̴ϽºÆ®¹ÙÀÌ¿ÀÁ¦¾à(ÁÖ) ÀλçºÎ¹® 10³âÀÌ»ó °æ·ÂÀÚ ¸ðÁý
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Àλç/ÀÎÀç°³¹ß/ä¿ë/±³À° |
10³â¡è |
ä¿ë½Ã |
11.30 |
|
|
(ÁÖ)ÀϽŹÙÀÌ¿Àºê·£Ä¡ |
ÀÌÈÇбâ±â °ü·Ã ¿µ¾÷ »ç¿ø ¸ðÁý
¼¿ï Á߶û±¸ | °íµîÇб³ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
°æ·Â¹«°ü |
ä¿ë½Ã |
03.13 |
|
|
(ÁÖ)ÆÒÁ¨ |
ÀÇ»ç, ¾à»ç ¶Ç´Â ÇѾà»ç´ÔÀ» ¸ð½Ê´Ï´Ù.
°æ±â ¼ö¿ø½Ã ¿µÅ뱸 | Çз¹«°ü |
˂ȍ |
°æ·Â¹«°ü |
ä¿ë½Ã |
03.02 |
|
|
ÁÖ½Äȸ»ç ¿¢¼ÒÁ¨ |
´ëÀü (ÁÖ)¿¢¼ÒÁ¨ ÀÌÄ«¿îÆ® °æ·ÂÀÚ ¸ðÁý
´ëÀü À¯¼º±¸ | Çз¹«°ü |
ÀϹݻ繫/Áö¿ø/¹®¼ÀÛ¼º |
1³â¡è |
ä¿ë½Ã |
02.20 |
|
|
(ÁÖ)¾Ë¹ÙÀÌ¿À |
¿¹¼ºÀÇ·áÀç´Ü ¾ç»êº£µ¥½º´Ù º´¿ø ±¸¸Å°ü¸® °æ·ÂÁ÷(ÆÀÀå) ä
°æ³² ¾ç»ê½Ã | ´ëÇÐ(2~3³â) Á¹¾÷ |
»ý»êÁö¿ø/¹°·ù/±¸¸Å |
10³â¡è |
ä¿ë½Ã |
02.20 |
|
|
GSK |
[GlaxoSmithKline]Vaccines Medical Advisor
¼¿ï ¿ë»ê±¸ | ´ëÇпø(¹Ú»ç) Á¹¾÷ |
˂ȍ |
°æ·Â¹«°ü |
ä¿ë½Ã |
12.26 |
|
|
(ÁÖ)¿¡½º¾ØºñÄÚÆÛ·¹ÀÌ¼Ç |
¿µ¾÷ ½ÅÀÔ/°æ·ÂÁ÷¿ø ¸ðÁý
°æ±â ¾È¾ç½Ã µ¿¾È±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
¿µ¾÷°ü¸®/¿µ¾÷Áö¿ø |
°æ·Â¹«°ü |
ä¿ë½Ã |
12.22 |
|
|
(ÁÖ)ÀÎÆ®·Î¹ÙÀÌ¿ÀÆĸ¶ |
ÀÎÆ®·Î¹ÙÀÌ¿ÀÆĸ¶ ÀǾàÇ° Ç°Áúº¸ÁõÆÀQA ½ÅÀÔ°æ·Â ä¿ë°ø°í (
°æ±â ÆòÅýà | Çз¹«°ü |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
°æ·Â¹«°ü |
ä¿ë½Ã |
01.15 |
|
|
PRA Health Sciences |
[PRA Health Sciences] CRA I, II, III, Contract Represent
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
11.14 |
|